Abbott Laboratories (NYSE: ABT / NYSE Texas: ABT): Corporate Profile & Financials
Source: Abbott Laboratories Form 10-K FY2025
📋 Quick Facts
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Abbott Laboratories |
| Ticker Symbol | ABT |
| Primary Exchanges | New York Stock Exchange, NYSE Texas, SIX Swiss Exchange |
| Year Incorporated | 1900 |
| State of Incorporation | Illinois |
| Corporate Headquarters | 100 Abbott Park Road, Abbott Park, Illinois 60064-6400 |
| Telephone Number | (224) 667-6100 |
| I.R.S. Employer Identification No. | 36-0698440 |
| Chairman & Chief Executive Officer | Robert B. Ford |
| Executive Vice President & Chief Financial Officer | Philip P. Boudreau |
| Vice President, Finance & Controller | John A. McCoy, Jr. |
| Executive Vice President, General Counsel & Secretary | Elizabeth C. Cushman |
| Global Employee Count | Approximately 115,000 employees |
| Geographic Employee Distribution | 69% employed outside of the United States |
| Global Manufacturing Footprint | 89 manufacturing facilities worldwide |
| Reportable Operating Segments | Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, Medical Devices |
| Pending Strategic Acquisition | Exact Sciences Corporation (Definitive agreement signed Nov 19, 2025) |
| Shareholders of Record | 29,122 (as of January 31, 2026) |
| Common Shares Outstanding | 1,737,682,887 shares (as of January 31, 2026) |
| Investor Relations Website | www.abbottinvestor.com |
🏢 The Corporate Identity: Who They Are & Where They Came From
The Big Picture
Abbott Laboratories is an Illinois corporation operating as a broad-based global healthcare leader. The company’s principal business encompasses the discovery, development, manufacture, and sale of a diversified line of healthcare products across four primary segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products.
Abbott conducts operations globally, generating 61.37% of its net sales in international markets outside the United States. Its broad healthcare footprint spans specialized medical technologies, commercial laboratory diagnostic systems, infant and adult nutritional formulas, and branded generic pharmaceuticals tailored for key emerging markets.
- Total Consolidated Net Sales (2025): $44,328 million
- Total Global Workforce: Approximately 115,000 employees across 160+ countries
- Operating Margin Profile (2025): 18.2% of total net sales
The Founders & Their Legacy
Abbott Laboratories traces its foundation back to 1900, when it was incorporated in the State of Illinois. Over more than a century of continuous operation, the company has expanded from a local pharmaceutical maker into a multi-billion-dollar international healthcare enterprise.
The company maintains a sustained focus on human capital as a core business driver. As of December 31, 2025, women represented 47% of Abbott’s U.S. workforce, 46% of its global workforce, and 44% of its managerial ranks. Executive compensation at Abbott is explicitly tied to human capital management objectives to sustain an inclusive organizational culture.
The Journey: History & Evolution
Abbott’s strategic trajectory has been shaped by continuous organic research and targeted inorganic expansion. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation, a transaction designed to mark Abbott’s strategic entry into the cancer diagnostics market.
Prior acquisitions have similarly broadened Abbott’s technological ecosystem. On April 27, 2023, Abbott acquired Cardiovascular Systems, Inc. (CSI) for $20 per common share, representing a total purchase price of $851 million in cash. CSI’s orbital atherectomy system expanded Abbott’s vascular device portfolio. On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc., accelerating its development of connected, personalized diabetes management tools.
- Exact Sciences Acquisition Consideration: $105 per common share in cash ($21 billion equity value, $23 billion enterprise value)
- Exact Sciences Net Debt Absorption: Approximately $1.8 billion
- CSI Acquisition Purchase Price: $851 million cash consideration
The Corporate Umbrella
Abbott Laboratories serves as the ultimate parent corporation for a global network of consolidated domestic and foreign subsidiaries, as well as variable interest entities for which it acts as the primary beneficiary. Intercompany accounts and transactions are eliminated upon financial consolidation.
The corporation’s global activities are supported by centralized corporate functions, dedicated research centers, and specialized regional manufacturing units operating across North America, Europe, Asia-Pacific, Latin America, and emerging markets.
⚙️ The Business Engine: What They Do & Where They Operate
The Core Divisions
Abbott structures its global operations into four reportable business segments, alongside non-segment corporate activities. Each division addresses specific healthcare verticals with dedicated manufacturing, commercial, and regulatory infrastructure.
The Medical Devices segment develops rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care devices. Diagnostic Products offers core laboratory, transfusion medicine, molecular, point-of-care, and rapid diagnostic platforms. Nutritional Products manufactures pediatric and adult nutritional formulas. Established Pharmaceutical Products markets branded generic pharmaceuticals in emerging markets outside the United States.
| Segment Name | 2025 Net Sales ($ millions) | % Share of Total Revenue | Cost of Products Sold ($ millions) | R&D Expenses ($ millions) | SG&A Expenses ($ millions) | Operating Earnings ($ millions) | Segment Assets ($ millions) |
|---|---|---|---|---|---|---|---|
| Medical Devices | 21,387 | 48.25% | 6,973 | 1,753 | 5,449 | 7,212 | 10,689 |
| Diagnostic Products | 8,937 | 20.16% | 4,984 | 602 | 1,611 | 1,740 | 8,273 |
| Nutritional Products | 8,451 | 19.06% | 4,569 | 213 | 2,111 | 1,558 | 4,791 |
| Established Pharmaceuticals | 5,536 | 12.49% | 2,615 | 176 | 1,455 | 1,290 | 3,540 |
| Other / Corporate | 17 | 0.04% | — | — | — | (3,737) | 59,420 |
| Consolidated Total | 44,328 | 100.00% | 19,319 | 2,942 | 12,332 | 8,053 | 86,713 |
The segment data underscores the scale of Medical Devices, which generated 48.25% of total company sales and $7.212 billion in operating earnings in 2025. Margins in Medical Devices were supported by double-digit organic growth across continuous glucose monitoring, structural heart, electrophysiology, and rhythm management platforms. Conversely, Diagnostic Products operating income declined to $1.740 billion in 2025 due to lower demand for COVID-19 rapid testing products and market headwinds in China.
The Global Product Catalog
Abbott maintains a deep product portfolio categorized into specific product lines within each operating division. Sales performance across these detailed commercial lines reflects shifting global demand dynamics and product adoption cycles.
| Reportable Segment | Product Line Category | 2025 Net Sales ($ millions) | 2024 Net Sales ($ millions) | 2023 Net Sales ($ millions) | Latest YoY (%) |
|---|---|---|---|---|---|
| Established Pharmaceuticals | Key Emerging Markets | 4,167 | 3,858 | 3,807 | +8.01% |
| Established Pharmaceuticals | Other Emerging Markets | 1,369 | 1,336 | 1,259 | +2.47% |
| Nutritional Products | International Pediatric Nutritionals | 1,816 | 1,815 | 1,957 | +0.06% |
| Nutritional Products | U.S. Pediatric Nutritionals | 2,158 | 2,208 | 1,977 | -2.26% |
| Nutritional Products | International Adult Nutritionals | 3,029 | 2,909 | 2,784 | +4.13% |
| Nutritional Products | U.S. Adult Nutritionals | 1,448 | 1,481 | 1,436 | -2.23% |
| Diagnostic Products | Core Laboratory | 5,360 | 5,235 | 5,159 | +2.39% |
| Diagnostic Products | Molecular | 517 | 521 | 574 | -0.77% |
| Diagnostic Products | Point of Care | 606 | 588 | 565 | +3.06% |
| Diagnostic Products | Rapid Diagnostics | 2,454 | 2,997 | 3,690 | -18.12% |
| Medical Devices | Rhythm Management | 2,649 | 2,390 | 2,255 | +10.84% |
| Medical Devices | Electrophysiology | 2,764 | 2,467 | 2,195 | +12.04% |
| Medical Devices | Heart Failure | 1,448 | 1,279 | 1,161 | +13.21% |
| Medical Devices | Vascular | 2,995 | 2,837 | 2,681 | +5.57% |
| Medical Devices | Structural Heart | 2,523 | 2,246 | 1,944 | +12.33% |
| Medical Devices | Neuromodulation | 1,010 | 962 | 890 | +4.99% |
| Medical Devices | Diabetes Care | 7,998 | 6,805 | 5,761 | +17.53% |
Commercial trends across sub-segments reveal robust momentum in Diabetes Care, where continuous glucose monitoring systems generated $7.6 billion in 2025 sales compared to $6.4 billion in 2024. In contrast, Rapid Diagnostics sales dropped from $3.690 billion in 2023 to $2.454 billion in 2025 as total COVID-19 testing-related sales contracted from $1.6 billion in 2023 to $747 million in 2024 and $297 million in 2025.
The Names You Know
Abbott markets its products under globally recognized proprietary brand names protected by trademarks and patents expiring between 2026 and 2046.
- Medical Devices Brands: FreeStyle Libre®, Lingo™, Aveir®, Assurity MRI®, Gallant®, TactiFlex™, Volt™, HeartMate®, CardioMEMS®, XIENCE®, MitraClip®, TriClip®, Navitor®, Proclaim® XR, Eterna®, Liberta RC®.
- Nutritional Brands: Similac®, Similac® 360 Total Care®, EleCare®, Ensure®, Ensure® Max Protein, Glucerna®, PediaSure®, Pedialyte®, Jevity®, Nepro®.
- Diagnostics Brands: Alinity®, ARCHITECT®, Cell-Dyn®, i-STAT®, BinaxNOW®, Panbio®, ID NOW®, Afinion®, AlinIQ®.
- Established Pharmaceuticals Brands: Creon™, Duspatal™, Heptral™, Duphaston™, Femoston™, Lipanthyl™, TriCor™, Serc™, Brufen™, Influvac™.
Mapping the Global Reach
Abbott operates across international jurisdictions, dividing its commercial reach between the United States and international markets (including Key Emerging Markets and developed foreign economies).
| Geographic Region / Country | 2025 Net Sales ($ millions) | % Share of 2025 Total Net Sales | 2024 Net Sales ($ millions) | 2023 Net Sales ($ millions) | Latest YoY (%) |
|---|---|---|---|---|---|
| United States | 17,126 | 38.63% | 16,323 | 15,452 | +4.92% |
| Germany | 2,759 | 6.22% | 2,539 | 2,345 | +8.66% |
| China | 1,907 | 4.30% | 2,113 | 2,253 | -9.75% |
| Switzerland | 1,871 | 4.22% | 1,747 | 1,638 | +7.10% |
| India | 1,871 | 4.22% | 1,817 | 1,750 | +2.97% |
| Japan | 1,475 | 3.33% | 1,441 | 1,513 | +2.36% |
| United Kingdom | 1,340 | 3.02% | 1,185 | 991 | +13.08% |
| All Other Countries | 15,979 | 36.05% | 14,786 | 14,168 | +8.07% |
| Consolidated Total | 44,328 | 100.00% | 41,950 | 40,109 | +5.67% |
The geographic data reflects sustained growth in the United States, Germany, Switzerland, India, and the United Kingdom. Sales in China declined from $2.253 billion in 2023 to $1.907 billion in 2025, influenced by local market dynamics and government volume-based procurement programs in diagnostics.
The Brick & Mortar Footprint
Abbott owns or leases approximately 44 million square feet of real estate globally, of which approximately 65% is owned directly by the company. Its corporate headquarters in Abbott Park, Illinois, are fully owned.
The company operates 89 dedicated manufacturing facilities distributed across its four business divisions worldwide:
- Medical Devices Manufacturing Sites: 33 facilities
- Established Pharmaceutical Products Manufacturing Sites: 22 facilities
- Diagnostic Products Manufacturing Sites: 21 facilities
- Nutritional Products Manufacturing Sites: 13 facilities
Primary research and development facilities in the United States are located in California, Illinois, Minnesota, New Jersey, and Ohio. International research and development centers operate in Colombia, India, Singapore, Spain, and the United Kingdom.
📊 The Financial Health: The Global Numbers Simplified
Earnings, Expenses, & Take-Home Profits
The Consolidated Statement of Earnings summarizes Abbott’s financial results over the three-year period ended December 31, 2025.
| Financial Metric ($ in millions, except per share) | FY2025 | FY2024 | FY2023 | Latest YoY (%) |
|---|---|---|---|---|
| Net Sales | 44,328 | 41,950 | 40,109 | +5.67% |
| Cost of products sold (excl. amortization of intangibles) | 19,319 | 18,706 | 17,975 | +3.28% |
| Amortization of intangible assets | 1,682 | 1,878 | 1,966 | -10.44% |
| Research and development | 2,942 | 2,844 | 2,741 | +3.45% |
| Selling, general and administrative | 12,332 | 11,697 | 10,949 | +5.43% |
| Total Operating Cost and Expenses | 36,275 | 35,125 | 33,631 | +3.27% |
| Operating Earnings | 8,053 | 6,825 | 6,478 | +17.99% |
| Interest expense | 493 | 559 | 637 | -11.81% |
| Interest income | (308) | (344) | (385) | -10.47% |
| Net foreign exchange (gain) loss | (50) | (27) | 41 | +85.19% |
| Other (income) expense, net | (548) | (376) | (479) | +45.74% |
| Earnings before Taxes | 8,466 | 7,013 | 6,664 | +20.72% |
| Taxes on Earnings | 1,942 | (6,389) | 941 | N/M |
| Net Earnings | 6,524 | 13,402 | 5,723 | -51.32% |
| Basic Earnings Per Common Share ($) | 3.73 | 7.67 | 3.28 | -51.37% |
| Diluted Earnings Per Common Share ($) | 3.72 | 7.64 | 3.26 | -51.31% |
Analysis of the profit and loss account shows expanding operating profitability. Operating earnings increased 17.99% from $6.825 billion in 2024 to $8.053 billion in 2025, driven by higher gross margins resulting from margin improvement initiatives across manufacturing operations.
Net earnings for 2024 reflected a $7.5 billion non-cash tax benefit arising from valuation allowance adjustments following the corporate restructuring of foreign affiliates. In 2025, tax expense returned to a standard rate structure of 22.9%, including a $610 million non-cash tax expense adjusting deferred tax assets recognized in prior periods.
Assets, Debts, & Corporate Wealth
The Consolidated Balance Sheet details Abbott’s capital structure, asset composition, and liquidity provisions as of December 31, 2025, and 2024.
| Balance Sheet Item ($ in millions) | As of Dec 31, 2025 | As of Dec 31, 2024 | Latest YoY (%) |
|---|---|---|---|
| Cash and cash equivalents | 8,522 | 7,616 | +11.90% |
| Investments (bank time deposits, U.S. treasuries) | 417 | 351 | +18.80% |
| Trade receivables, net | 7,929 | 6,925 | +14.50% |
| Total inventories | 6,488 | 6,194 | +4.75% |
| Other prepaid expenses and receivables | 2,640 | 2,570 | +2.72% |
| Total Current Assets | 25,996 | 23,656 | +9.89% |
| Long-term investments | 918 | 886 | +3.61% |
| Net property and equipment | 11,816 | 10,658 | +10.87% |
| Intangible assets, net of amortization | 5,526 | 6,647 | -16.86% |
| Goodwill | 24,035 | 23,108 | +4.01% |
| Deferred income taxes and other assets | 18,422 | 16,459 | +11.93% |
| Total Assets | 86,713 | 81,414 | +6.51% |
| Trade accounts payable | 4,240 | 4,195 | +1.07% |
| Salaries, wages, and commissions | 1,745 | 1,701 | +2.59% |
| Other accrued liabilities | 5,812 | 5,143 | +13.01% |
| Dividends payable | 1,097 | 1,024 | +7.13% |
| Income taxes payable | 569 | 594 | -4.21% |
| Current portion of long-term debt | 3,033 | 1,500 | +102.20% |
| Total Current Liabilities | 16,496 | 14,157 | +16.52% |
| Long-term debt | 9,896 | 12,625 | -21.62% |
| Post-employment obligations and other long-term liabilities | 7,550 | 6,731 | +12.17% |
| Total Shareholders’ Investment | 52,771 | 47,901 | +10.17% |
| Total Liabilities and Shareholders’ Investment | 86,713 | 81,414 | +6.51% |
Abbott maintained working capital of $9.5 billion as of December 31, 2025, unchanged from $9.5 billion at year-end 2024. Total debt stood at $12.929 billion ($3.033 billion current portion and $9.896 billion long-term portion). Goodwill stood at $24.035 billion, while intangible assets totaled $5.526 billion net of accumulated amortization.
Cash Flow: Tracking the Money Movement
The Consolidated Statement of Cash Flows details operational cash generation, capital investments, debt servicing, and equity distributions.
| Cash Flow Activity ($ in millions) | FY2025 | FY2024 | FY2023 | Latest YoY (%) |
|---|---|---|---|---|
| Net Earnings | 6,524 | 13,402 | 5,723 | -51.32% |
| Depreciation | 1,434 | 1,340 | 1,277 | +7.01% |
| Amortization of intangible assets | 1,682 | 1,878 | 1,966 | -10.44% |
| Share-based compensation | 664 | 673 | 644 | -1.34% |
| Investing and financing losses, net | 65 | 482 | 126 | -86.51% |
| Changes in working capital & taxes | (803) | (9,217) | (2,475) | -91.29% |
| Net Cash From Operating Activities | 9,566 | 8,558 | 7,261 | +11.78% |
| Acquisitions of property and equipment (Capex) | (2,171) | (2,207) | (2,202) | -1.63% |
| Acquisitions of businesses and technologies, net | (105) | — | (877) | – |
| Purchases/Sales of investment securities & Other | (146) | (131) | (54) | +11.45% |
| Net Cash From (Used in) Investing Activities | (2,422) | (2,338) | (3,133) | +3.59% |
| Proceeds/Repayments of debt (net) | (1,614) | (537) | (2,475) | +200.56% |
| Purchases of common shares (Repurchases) | (893) | (1,295) | (1,227) | -31.04% |
| Proceeds from stock options exercised | 396 | 264 | 167 | +50.00% |
| Dividends paid | (4,116) | (3,836) | (3,556) | +7.30% |
| Other financing activities | (82) | — | — | – |
| Net Cash From (Used in) Financing Activities | (6,309) | (5,404) | (7,091) | +16.75% |
| Effect of exchange rate changes | 71 | (96) | (23) | N/M |
| Net Increase (Decrease) in Cash and Cash Equivalents | 906 | 720 | (2,986) | +25.83% |
| Cash and Cash Equivalents, Beginning of Year | 7,616 | 6,896 | 9,882 | +10.44% |
| Cash and Cash Equivalents, End of Year | 8,522 | 7,616 | 6,896 | +11.90% |
Operating cash flow reached $9.566 billion in 2025, driven by expanding earnings in Medical Devices and Established Pharmaceuticals and effective working capital management. Operational cash inflows fully funded $2.171 billion in capital expenditures, $4.116 billion in common stock dividends, and $893 million in share purchases.
Funding the Future: R&D and Expansion Spending
Abbott invests in internal research and development programs and capital property expansion. R&D expenditure reached $2.942 billion in 2025, $2.844 billion in 2024, and $2.741 billion in 2023. R&D spending is targeted at approximately 7% of total sales in 2026.
Contractual commitments as of December 31, 2025, include scheduled debt maturities, interest commitments, and lease liabilities:
- Debt Principal Maturities: $3.0 billion in 2026; $700 million in 2027; $653 million in 2028; $591 million in 2029; $650 million in 2030; $7.4 billion thereafter
- Projected Interest Obligations: $485 million in 2026; $401 million in 2027; $395 million in 2028; $386 million in 2029; $377 million in 2030; $4.3 billion thereafter
- Undiscounted Operating Lease Commitments: $1,391 million total ($316 million due in 2026)
- Acquisition Bridge Facility Commitment: $20.0 billion 364-day senior unsecured facility for Exact Sciences transaction
🗺️ The Corporate Family Tree: Structure & Investments
Subsidiaries, Associates, & Shared Ventures
Abbott operates through consolidated legal entities globally. Significant financing and operating subsidiaries include Abbott Ireland Financing DAC, Abbott Laboratories Inc., Bigfoot Biomedical, Inc., and Cardiovascular Systems, Inc.
Subsidiary operations are fully integrated within reportable segments based on product functionality. Intercompany profits and transactions are eliminated upon consolidation.
Strategic Investments & Minority Stakes
Abbott holds equity and debt investments reported within Long-Term Investments on the Consolidated Balance Sheet ($918 million total as of December 31, 2025).
- Rabbi Trust Investments: $323 million in mutual funds held for non-qualified deferred compensation plan liabilities
- Equity Method Investments: $131 million carrying value in entities over which Abbott exercises significant influence
- Non-Publicly Traded Equity Securities: $124 million carrying value measured at cost minus impairment plus/minus observable price changes
- Publicly Traded Equity Securities: $20 million fair value subject to mark-to-market earnings adjustments
👥 Power & Control: Who Pulls the Strings?
The Brain Trust: Board of Directors & Executive Leadership
Abbott’s executive leadership team manages corporate strategy and global operations across divisions.
- Robert B. Ford: Chairman of the Board and Chief Executive Officer (Officer since 2008; CEO since 2020; Chairman since 2021).
- Philip P. Boudreau: Executive Vice President, Finance and Chief Financial Officer (Officer since 2020; CFO since 2023).
- Elizabeth C. Cushman: Executive Vice President, General Counsel and Secretary (Officer since 2023; General Counsel since 2025).
- Lisa D. Earnhardt: Executive Vice President and Group President, Medical Devices (Officer since 2019).
- Mary K. Moreland: Executive Vice President, Human Resources (Officer since 2019).
- Louis H. Morrone: Executive Vice President, Core Diagnostics (Officer since 2017).
- Daniel Salvadori: Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products (Officer since 2014).
- Christopher J. Scoggins: Executive Vice President, Diabetes Care (Officer since 2015).
- Eric Shroff: Senior Vice President, Rapid and Molecular Diagnostics (Officer since 2018).
- John A. McCoy, Jr.: Vice President, Finance and Controller (Officer since 2021).
The Board of Directors signatories on the Annual Report include Robert B. Ford, Nita Ahuja, M.D., Robert J. Alpern, M.D., Claire Babineaux-Fontenot, Sally E. Blount, Ph.D., Paola Gonzalez, Michelle A. Kumbier, Darren W. McDew, Nancy McKinstry, Michael G. O’Grady, Michael F. Roman, Daniel J. Starks, and John G. Stratton.
Who Owns the Stock?
Abbott Laboratories is publicly traded on the New York Stock Exchange and NYSE Texas under the ticker symbol ABT. As of January 31, 2026, there were 29,122 holders of record of Abbott common shares, with 1,737,682,887 common shares outstanding.
On October 11, 2024, Abbott’s Board of Directors authorized a $7 billion share repurchase program. During 2025, Abbott repurchased 4.8 million common shares for $604 million, fully exhausting a prior 2021 program and utilizing a portion of the 2024 program. As of December 31, 2025, $6.69 billion remained available for repurchase under the 2024 authorization.
🎯 The Strategic Outlook: Future Plans & Potential Pitfalls
Competitive Advantages & Economic Moats
Abbott maintains competitive advantages through proprietary technological platforms, brand equity, global market distribution, and intellectual property portfolios.
- Diabetes Care Leadership: FreeStyle Libre CGM platforms generated $7.6 billion in 2025 revenue, supported by expanding reimbursement coverage and continuous product sensing enhancements.
- Structural Heart Innovation: First-mover minimally invasive transcatheter systems, including MitraClip, TriClip, Navitor, and Tendyne.
- Global Diversification: Revenue distribution across medical devices, diagnostic testing, nutritional products, and generic pharmaceuticals reduces single-market risk.
- Emerging Markets Commercial Scale: Established Pharmaceuticals provides high-volume, branded generic medicines in foreign markets representing 37% of total company sales.
What Could Go Wrong? Key Challenges & Business Risks
Abbott faces business, regulatory, legal, and macroeconomic risk factors that could impact operational performance.
- Preterm Infant Formula Litigation: As of January 31, 2026, Abbott was named in 1,760 lawsuits alleging preterm infants developed necrotizing enterocolitis (NEC) from cow’s milk-based formula. A Missouri state jury awarded $495 million in damages in July 2024 (currently under appeal by Abbott). Three federal bellwether cases resulted in summary judgments for Abbott.
- Governmental Investigations & Qui Tam Suits: The U.S. Department of Justice (DOJ) is conducting a criminal investigation into powdered infant formula manufacturing at the Sturgis, Michigan facility. In November 2025, the DOJ intervened in a civil qui tam lawsuit alleging False Claims Act violations regarding Sturgis operations. The FTC is investigating infant formula WIC contract bidding.
- Exact Sciences Financing & Debt Absorption: Abbott plans to absorb $1.8 billion of net debt and incur up to $20 billion in borrowings to complete the Exact Sciences acquisition, increasing leverage and debt servicing costs.
- Regulatory & Manufacturing Requirements: Strict FDA quality system regulations, consent decree compliance for infant formula manufacturing, and European Union Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) compliance obligations.
- Tax Controversies: Outstanding IRS Statutory Notices of Deficiency (SNODs) for tax years 2017 through 2020 seeking aggregate additional taxes exceeding $1.0 billion relating to foreign affiliate income reallocations (contested by Abbott in U.S. Tax Court). A $413 million tax assessment from Malaysian tax authorities is currently on appeal.
The Next Chapter: Growth & Expansion Initiatives
Abbott’s strategic roadmap emphasizes high-growth technology platforms and market expansions:
- Cancer Diagnostics Entry: Completion of the pending acquisition of Exact Sciences Corporation to establish a commercial position in early cancer detection and screening.
- Electrophysiology Expansion: U.S. launch and commercial scale-up of the Volt™ Pulsed Field Ablation (PFA) System and TactiFlex™ Duo Ablation Catheter for treating atrial fibrillation.
- Structural Heart Portfolio: Commercial rollout of the Tendyne™ TMVR system following FDA approval, and market expansion of TriClip® in Japan and Europe.
- Continuous Monitoring Ecosystem: Expanding FreeStyle Libre and Lingo continuous glucose and metabolic sensors into broader wellness, pre-diabetes, and non-diabetic applications.
- Alinity Platform Menu Expansion: Expanding test menus across Core Laboratory, Molecular, and Point of Care diagnostic platforms alongside GLP automation track integration.
The Verdict: Strategic Outlook & Conclusion
Abbott Laboratories enters 2026 with high operational momentum in Medical Devices, double-digit growth in continuous glucose monitoring and structural heart therapies, and a stable cash-generative profile ($9.566 billion operating cash flow in 2025). While legal proceedings surrounding preterm infant formula and increased debt execution for the pending $21 billion Exact Sciences acquisition represent near-term focal points, Abbott’s core operating businesses continue to expand gross and operating margins while funding R&D, capital growth, and shareholder returns.
Official Site: https://www.abbottinvestor.com
Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.